This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

• Status: Withdrawn
• Trial end date: 2009-06-01

Summary

To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.

• Phase: Phase 3

Details

• Lead Sponsor: Genta Incorporated
• Treatments: Fludarabine; Fludarabine phosphate; Oblimersen; Rituximab